vadadustat + digoxin

**Vadadustat + digoxin** is an investigational combination of two pharmaceutical agents used in a clinical pharmacology study to assess drug-drug interactions. Vadadustat is a small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis, acting by stabilizing HIF-α, thereby increasing endogenous erythropoietin production. Digoxin is a well-established cardiac glycoside used primarily for the treatment of atrial fibrillation and heart failure, functioning primarily as an inhibitor of the sodium-potassium ATPase in cardiac tissue. The combination has been evaluated in healthy volunteers to assess whether vadadustat affects the pharmacokinetics of digoxin, a substrate of P-glycoprotein (P-gp); studies showed that coadministration did not alter digoxin exposure[1][2][3][4].

Other names

vadadustatdigoxin